BeiGene Announces Approval for BRUKINSA (zanubrutinib) by Swissmedic for Treatment of Adult Patients with Waldenström’s Macroglobulinemia
With this approval, BRUKINSA is now approved in 44 markets as BeiGene continues to advance its global registration, including the...









